[ET Net News Agency, 5 July 2021] Akeso, Inc. (09926) said the company has received the
approval from the National Medical Products Administration (NMPA) of the People's Republic
of China to initiate an open-label, multicentre phase Ib/II clinical trial for the global
first-in-class novel drug Cadonilimab (PD-1/ CTLA-4 bi-specific antibody, research and
development code: AK104), an immunooncology therapy independently developed by the
company, and VEGFR-2 monoclonal antibody (research and development code: AK109) in
combination with/without chemotherapy for second-line treatment of advanced gastric
adenocarcinoma or gastroesophageal junction cancer.
This clinical trial in combination with VEGFR-2 focuses on patients with advanced
gastric cancer who have experienced failure of PD-(L)1 treatment, and is expected to
become a new hope for the second-line treatment of advanced gastric cancer. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09926 AKESO
Nominal 
48.400 +0.950 (+2.002%) Others
05/07/2021 11:32
Akeso (09926) gets clinical trial approval
| Remark: | Real time quote last updated: 25/04/2024 14:35 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |